Abstract
Based on gene expression data, we tested the P8A-CCL2 variant of the chemokine CCL2, able to interfere with the chemotactic properties of the parental molecule, in relapsing-remitting (RR)-EAE SJL. Only preventive treatment significantly delayed disease onset in a dose dependent manner. P8A-CCL2 administration, however, decreased demyelination, axonal loss and number of CNS infiltrating T cells and macrophages. Immunological analysis revealed that P8A-CCL2 does not act on Ag-specific T cell proliferation and does not interfere with the differentiation of IFNγ-releasing effectors T cells. These results suggest that the therapeutic mechanism of P8A-CCL2 may rely on interference with immune cell recruitment.
Original language | English |
---|---|
Pages (from-to) | 33-39 |
Number of pages | 7 |
Journal | Journal of Neuroimmunology |
Volume | 209 |
Issue number | 1-2 |
DOIs | |
Publication status | Published - Apr 30 2009 |
Keywords
- CCL2
- CCR2
- Chemokines
- EAE/MS
ASJC Scopus subject areas
- Immunology
- Clinical Neurology
- Immunology and Allergy
- Neurology